EU PAL-COPD: Evaluation of the ICLEAR-EU intervention to integrate palliative care in the treatment of people with advanced COPD and their family caregivers: An international stepped wedge cluster RCT in six European countries.

EU PAL-COPD：对 ICLEAR-EU 干预措施的评估，将姑息治疗纳入晚期 COPD 患者及其家庭护理人员的治疗中：在六个欧洲国家进行的国际阶梯式楔形集群随机对照试验。

• 批准号: 10109782
• 金额: $ 33.44万
• 依托单位: KING'S COLLEGE LONDON
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10109782
• 关键词: EU; PAL; COPD; Evaluation; ICLEAR

Chronic Obstructive Pulmonary Disease (COPD) is a devastating life-limiting lung disease with a high personal and societal burden. Worldwide, COPD is the third leading cause of death. The symptom burden of people with COPD is as severe and burdensome as the symptom burden of people with lung COPD. While palliative care in many countries is available for people with lung COPD, palliative care and good end-of-life care for people with COPD are not well integrated into their treatment by respiratory hospital teams in Europe. The EU PAL-COPD project is a multidisciplinary, interprofessional, international and intersectoral project aiming at evaluating the clinical and cost-effectiveness of the ICLEAR-EU intervention for people with advanced COPD in different healthcare systems in Europe. ICLEAR-EU is a person-centred and family-centred non-pharmacological service intervention in which respiratory teams in the hospital collaborate with interdisciplinary palliative care teams and with primary care to promote shared decision-making and advance care planning, improve symptom treatment and comfort care, and prevent re-hospitalization after an exacerbation. ICLEAR-EU is based on an existing intervention developed and pilot tested in the UK. In EU PAL-COPD, the effectiveness of ICLEAR-EU will be assessed with a stepped wedge cluster RCT in 1,224 people with advanced COPD in 18 hospitals across six European countries. It is hence the first large-scale international trial on systematic integration of palliative care in respiratory care for people with advanced COPD. Cost-effectiveness, robust mixed methods subgroup analyses and in-depth process and implementation evaluations are also included. EU PAL-COPD will improve the well-being and empowerment of people with COPD and their families and advance the state of the art by providing an innovative service model to the complex palliative and end-of-life care needs. User and stakeholder involvement is crucial throughout the project.

慢性阻塞性肺疾病（COPD）是一种毁灭性的生命肺部疾病，其个人和社会负担很高。 COPD在全球范围内是死亡的第三大主要原因。 COPD患者的症状负担与肺COPD患者的症状负担一样严重和繁重。虽然许多国家 /地区的姑息治疗可用于肺COPD的患者，姑息治疗和COPD患者的良好寿命护理并没有被欧洲的呼吸医院小组很好地融入他们的治疗中。欧盟PAL-COPD项目是一个跨学科，跨专业，国际和部门项目，旨在评估ICLEAR-eu干预的临床和成本效益，供欧洲不同医疗保健系统中的高级COPD患者进行ICLEAR-eu干预。 ICLEAR-eu是一个以人为中心的，以家庭为中心的非药物服务干预措施，医院的呼吸小组与跨学科的姑息治疗团队合作，并与初级保健一起促进共同的决策和提前护理计划，改善症状治疗和舒适的护理，并在恶化后防止重新疗养。 ICLEAR-eu是基于在英国开发和试点测试的现有干预措施。在欧盟PAL-COPD中，ICLEAR-eu的有效性将通过1,224人在六个欧洲国家的18家医院中的1,224人患者进行评估。因此，这是针对患有高级COPD的患者进行姑息治疗系统整合的第一个大规模国际试验。成本效益，强大的混合方法亚组分析以及深入的过程和实施评估也包括在内。欧盟Pal-COPD将改善COPD及其家人的人们的福祉和赋权，并通过向复杂的姑息治疗和寿命终止护理需求提供创新的服务模式来提高最新技术。在整个项目中，用户和利益相关者的参与至关重要。